Combination Chemoembolization and Radiofrequency Ablation for Hepatocellular Carcinoma Greater Than 3 cm (TACE-RFA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00479050|
Recruitment Status : Completed
First Posted : May 25, 2007
Last Update Posted : May 25, 2007
|Condition or disease||Intervention/treatment||Phase|
|Hepatocellular Carcinoma||Procedure: chemoembolization ,Radiofrequency ablation||Phase 1|
To assess whether the effectiveness of a combination of transcatheter arterial chemoembolization(TACE) and radiofrequency ablation(RFA) is superior to TACE and RFA alone in treatment of patients with hepatocellular carcinoma(HCC)greater than 3 cm and to analyze the factors affecting the outcomes.
The patients with HCC of 3 or fewer lesions, each 3cm greater in diameter entered this randomized controlled trial. The primary end point was survival, and the secondary end points were tumor response.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||291 participants|
|Intervention Model:||Single Group Assignment|
|Official Title:||Phase 1 Study of Combination Chemoembolization and Radiofrequency Ablation for Hepatocellular Carcinoma Greater Than 3 cm|
|Study Start Date :||January 2001|
|Study Completion Date :||December 2006|
- overall survival [ Time Frame: 5 years ]
- tumor response [ Time Frame: 1-6 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00479050
|Study Chair:||Wang Qi Liang, MD,PhD||Dept. of Radiology|